An animal model of emotional blunting in schizophrenia

PLoS ONE

Volumn 2, Issue 12, 2007, Pages

  Pietersen, Charmaine Y ^a,b   Bosker, Fokko J ^a   Doorduin, Janine ^a   Jongsma, Minke E ^a,c   Postema, Folkert ^a   Haas, Joseph V ^d   Johnson, Michael P ^d   Koch, Tineke ^a   Vladusich, Tony ^a,e   den Boer, Johan A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MCLEAN HOSPITAL   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; CLOZAPINE; DOPAMINE; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 3; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; PROTEIN C FOS;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BLUNTED AFFECT; BRAIN DYSFUNCTION; BRAIN REGION; CONDITIONING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; EMOTIONAL STRESS; EMOTIONALITY; FEAR; IMMUNOCYTOCHEMISTRY; INFORMATION PROCESSING; MALE; NEUROCHEMISTRY; NONHUMAN; PATHOLOGICAL ANATOMY; RAT; SCHIZOPHRENIA; ANIMAL; CONDITIONED REFLEX; EMOTION; METABOLISM; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, CLASSICAL; DOPAMINE; EMOTIONS; FEAR; GLUTAMIC ACID; MALE; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIC PSYCHOLOGY;

EID: 44449101682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001360     Document Type: Article

References (92)

1. Peroutka SJ, Synder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, scrotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518-1522.
2. Heinz A (2000) [The dopamine hypothesis of schizophrenia. New findings for an old theory] Dopaminhypothese der Schizophrenien. Neue Befunde hit cine alte Theorie. Nervenarzt 71: 54-57.
3. Jones HM, Pilowsky LS (2002) Dopamine and antipsychotic drug action revisited. Br J Psychiatry 181: 271-275.
4. Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42: 165-179.
5. Goyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174: 32-38.
6. Heresco-Levy U (2003) Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1113-1123.
7. Hofer E, Doby D, Anderer P, Dantendorfer K (2001) Impaired conditional discrimination learning in schizophrenia. Schizophr Res 51: 127-136.
8. O'Carroll RE (1995) Associative learning in acutely ill and recovered schizophrenic patients. Schizophr Res 15: 299-301.
9. Rushe TM, Woodruff PW, Murray RM, Morris RG (1999) Episodic memory and learning in patients with chronic schizophrenia. Schizophr Res 35: 85-96.
10. Edwards J, Partison PE, Jackson HJ, Wales RJ (2001) Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res 48: 235-253.
11. Cur RE, McGrath C, Chan RM, Schroeder L, Turner T, et al. (2002) An fMRI study of ficial emotion processing in patients with schizophrenia. Am J Psychiatry 159: 1992-1999.
12. Johnston PJ, Katsikitis M, Carr VJ (2001) A generalised deficit can account for problems in facial emotion recognition in schizophrenia. Biol Psychol 58: 203-227.
13. Paradiso S, Andreasen NC, Crespo-Facorro B, O'Leary DS, Watkins GL, et al. (2003) Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am J Psychiatry 160: 1775-1783.
14. Takahashi H, Koeda M, Oda K, Matsuda T, Matsushima E, et al. (2004) An fMRI study of differential neural response to affective pictures in schizophrenia. Neuroimage 22: 1247-1254.
15. Maren S, Fanselow MS (1996) The amygdala and fear conditioning: has the nut been cracked? Neuron 16: 237-240.
16. LeDoux J (1998) Fear and the brain: where have we been, and where are we going? Biol Psychiatry 44: 1229-1238.
17. Adolphs R, Tranel D, Damasio H, Damasio AR (1995) Fear and the human amygdala. J Neurosci 15: 5879-5891.
18. Exner C, Boucsein K, Degner D, Irle E, Weniger G (2004) Impaired emotional learning and reduced amygdala size in schizophrenia: a 3-month follow-up. Schizophr Res 71: 493-503.
19. Joyal CC, Laakso MP, Tiihonen J, Syvalahti E, Vilkman H, et al. (2003) The amygdala and schizophrenia: a volumetric magnetic resouance imaging study in first-episode, neuroleptic-naive patients. Biol Psychiatry 54: 1302-1304.
20. Niu L, Matsui M, Zhou SY, Hagino H, Takahashi T, et al. (2004) Volume reduction of the amygdala in patients with schizophrenia: a magnetic resonance imaging study. Psychiatry Res 132: 41-51.
21. Sachdev P, Brodary H, Cheang D, Cathcart S (2000) Hippocampus and amygdala volumes in elderly schizophrenic patients as assessed by magnetic resonance imaging. Psychiatry Clin Neurosci 54: 105-112.
22. Taylor SF, Liberzon I, Decker LR, Koeppe RA (2002) A functional anatomic study of emotion in schizophrenia. Schizophr Res 58: 159-172.
23. Fahim, C, Stip E, Mancini-Marie A, Mensour B, Boulay LJ, et al. (2005) Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res 140: 1-15.
24. Aleman A; Kahn RS (2005) Strange feelings: do amygdala abnormalities dysregulate die emotional brain in schizophrenia? Prog Neurobiol 77: 283-298.
25. Hulshoff Pol HE, Schnack HG, Mandl RC, van Haren NE, Koning H, et al. (2001) Focal gray matter density changes in schizophrenia. Arch Gen Psychiatry 58: 1118-1125.
26. Castner SA, Goldman-Rakic PS (2003) Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates. Biol Psychiatry 54: 105-110.
27. Grace AA (2000) Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 31: 330-341.
28. Marcotte ER, Pearson DM, Srivastava LK (2001) Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 26: 395-410.
29. Schanz G, Koch M (2000) Blockade of NMDA receptors in the amygdala prevents latent inhibition of fear-conditioning. Uarn Mem 7: 393-399.
30. Schmajuk NA (2001) Hippocampal dysfunction in schizophrenia. Hippocampus 11: 599-613.
31. Goosens KA, Maren S (2003) Pretraining NMDA receptor blockade in the basolateral complex, but not the central nucleus, of the amygdala prevents savings of conditional few. Behav Neurosci 117: 738-750.
32. Yagi K, Onaka T, Yoshida A (1998) Role of NMDA receptors in the emotional memory associated with neuroendocrine responses to conditioned fear stimuli in the rat. Neurosci Res 30: 279-286.
33. Johnson DM, Baker JD, Azorlosa JL (2000) Acquisition, extinction, and reinstatement of Pavlovian fear conditioning: the roles of the NMDA receptor and nitric oxide. Brain Res 857: 66-70.
34. Kleim JA, Lussnig E, Schwarz ER, Comery TA, Greenough WT (1996) Synaptogenesis and Fos expression in the motor cortex of the aduh rat after motor skill learning. J Neurosci 16: 4529-4535.
35. Frankland PW, Bontempi B, Talton LE, Kaczmarek L, Silva AJ (2004) The involvement of the anterior cingulate cortex in remote contextual fear memory. Science 304: 881-883.
36. Can YJ, Ren WH, Zhang YQ, Zhao ZQ (2004) Contributions of the anterior cingulate cortex and amygdala to pain- and fear-conditioned place avoidance in rats. Pain 110: 343-353.
37. Cardinal RN, Parkinson JA, Hall J, Everitt BJ (2002) Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev 26: 321-352.
38. Han CJ, O'Tuathaigh CM, van Trigt L, Quinn JJ, Fanselow MS, et al. (2003) Trace but not delay fear conditioning requires attention and the anterior cingulate cortex. Proc Natl Acad Sci U S A 100: 13087-13092.
39. Bush G, Luu P, Posner MI (2000) Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci 4: 215-222.
40. Reynolds SM, Berridge KC (2003) Glutamate motivational ensembles in nucleus accumbens: rostrocaudal shell gradients of fear and feeding. Eur J Neurosci 17: 2187-2200.
41. Salamone JD, Correa M, Mingote SM, Weber SM (2005) Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol 5: 34-41.
42. Johnson LR, Aylward RL, Hussain Z, Totterdell S (1994) Input from the amygdala to the rat nucleus accumbens: its relationship with tyrosine hydroxylase immunoreactivity and identified neurons. Neuroscience 61: 851-865.
43. Lindefors N, Barati S, O'Connor WT (1997) Differential effects of single and repeated ketamine administration on dopamine, scrotonin and GABA transmission in rat medial prefrontal cortex. Brain Res 759: 205-212.
44. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706.
45. Verma. A, Moghaddam B (1996) NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by doparnine. J Neurosci 16: 373-379.
46. Levinson DF (1991) Pharmacologic treatment of schizophrenia. Clin Ther 13: 326-352.
47. Yamamoto BK, Cooperman MA (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159-4166.
48. Daly DA, Moghaddam B (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152: 61-64.
49. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812: 65-75.
50. Walker DL, Davis M (2002) The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 71: 379-392.
51. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, et al. (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4: 131-144.
52. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
53. Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291: 161-170.
54. Homayoun H, Jackson ME, Moghaddam B (2005) Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93: 1989-2001.
55. Harich S, Gross G, Bespalov A (2007) Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 192: 511-519.
56. Abekawa T, Ito K, Koyama T (2007) Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch Pharmacol 375: 261-71.
57. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787-794.
58. Dunn MJ, Killcross S (2006) Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists. Psychopharmacology (Berl) 188: 183-192.
59. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
60. Pietersen CY, Bosker FJ, Postema F, Fokkema DS, Korf J, et al. (2006) Ketamine administration disturbs behavioural and distributed neural correlates of fear conditioning in the rat. Prog Neuropsychopharmacol Biol Psychiatry 30: 1209-1218.
61. Imre G, Fokkema DS, Boer JA, Ter Horst GJ (2006) Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 69: 338-345.
62. Bolles RC, Collier AC (1976) The effect of predictive cues on freezing in rats. Animal Learning and Behavior 4: 6-8.
63. Holahan MR, White NM (2002) Conditioned memory modulation, freezing, and avoidance as measures of amygdala-rnediated conditioned fear. Neurobiol Learn Mem 77: 250-275.
64. Sharp JW (1997) Phencyclidine (PCP) acts at sigma sites to induce c-fos gene expression. Brain Res 758: 51-58.
65. Swanson LW (1992) Brain maps: Structure ofthe rat brain. Amsterdam: Elsevier Publishing company.
66. Montgomery DC (1984) Design and Analysis of Experiments. New York: John Wiley and Sons.
67. Miliken GA, Johnson DE (1992) Analysis of Messy Data Volume 1: Designed Experiments. New York: Chapman and Hall/CRC.
68. Davidson RJ, Irwin W (1999) The functional neuroanatomy of emotion and affective style. Trends Cogn Sci 3: 11-21.
69. Rex A, Voigt JP, Voits M, Fink H (1998) Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav 59: 677-683.
70. Sharma V (2003) Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disord 5: 48-52.
71. Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, et al. (1993) Antipsychofic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 34: 119-121.
72. Olney JW, Farber NB (1994) Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry 55: 43-46.
73. Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, et al. (2005) The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol 506: 209-219.
74. Ma J, Ye N, Cohen BM (2006) Expression of noradrenergic alpha1, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 30: 647-57.
75. Reynolds GP (1983) Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305: 527-529.
76. Fanselow MS, Kim JJ (1994) Acquisition of contextual Pavlovian fear conditioning is blocked by application of an NMDA receptor antagonist D,L-2-amino-5-phosphonovaleric acid to the basolateral amygdala. Behav Neurosci 108: 210-212.
77. Killcross S, Robbins TW, Everitt BJ (1997) Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Nature 388: 377-380.
78. Koo JW, Han JS, Kim JJ (2004) Selective neurotoxic lesions of basolateral and central nuclei of the amygdala produce differential effects on fear conditioning. J Neurosci 24: 7654-7662.
79. Pare D, Royer S, Smith Y, Lang EJ (2003) Contextual inhibaory gating of impulse traffic in the intra-amygdaloid network. Ann N Y Acad Sci 985: 78-91.
80. Miscrendino MJ, Sananes CB, Melia KR, Davis M (1990) Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 345: 716-718.
81. Monaghan DT, Cotman CW (1985) Distribution of N-methyl-D-aspartate-sensitive L-[3H]glutamate-binding sites in rat brain. J Neurosci 5: 2909-2919.
82. Savonenko, A, Werka T, Nikolaev E, Zielinski K, Kaczmarek I, (2003) Complex effects of NMDA receptor antagonist APV in the basolateral amygdala on acquisition of two-way avoidance reaction and long-term fear memory. Learn Mem 10: 293-303.
83. Kleim JA, Lussnig E, Schwarz ER, Comery TA, Greenough WT (1996) Synaptogenesis and Fos expression in the motor cortex of the adult rat after motor skill learning. J Neurosci 16: 4529-4535.
84. Shots TJ, Mathew PR (1998) NMDA receptor antagonism in the lateral/ basolateral but not central nucleus of the amygdala prevents the induction of facilitated learning in response to stress. Learn Mem 5: 220-230.
85. Pezze MA, Feldon J (2004) Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 74: 301-320.
86. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamilin and PCP have direct effects on the dopamine D(2) and scrotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7: 837-844.
87. Marowsky A, Yanagawa Y, Obata K, Vogt KE (2005) A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron 48: 1025-1037.
88. Borowski TB, Kokkinidis L (1998) The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behav Neurosci 112: 952-965.
89. Greba Q, Kokkinidis L (2000) Peripheral and intraamygdalar administration of the dopamine D1 receptor antagonist SCH 23390 blocks fear-potentiated startle but not shock reactivity or the shock sensitization of acoustic startle. Behav Neurosci 114: 262-272.
90. Inoue T, Izumi T, Maki Y, Muraki I, Koyama T (2000) Effect of the dopamine D(1/5) antagonist SCH 23390 on the acquisition of conditioned lear. Pharmacol Biochem Behav 66: 573-578.
91. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
92. Kane JM (1989) The current status of neuroleptic therapy. J Clin Psychiatry 50: 322-328.